Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Relative Bioavailability Study Comparing The Pharmacokinetics Of Aramchol Meglumine Granules For Oral Suspension To Aramchol Free Acid 300 mg Tablets In Healthy Volunteers

Next Previous
Search
Trial Profile

A Phase 1 Relative Bioavailability Study Comparing The Pharmacokinetics Of Aramchol Meglumine Granules For Oral Suspension To Aramchol Free Acid 300 mg Tablets In Healthy Volunteers

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Icomidocholic acid (Primary) ; Icomidocholic acid
  • Indications Cholelithiasis; Fibrosis; Inflammatory bowel diseases; Lipodystrophy; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Focus Pharmacokinetics
  • Sponsors Galmed Pharmaceuticals

Most Recent Events

  • 10 Apr 2025 According to Galmed Pharmaceuticals media release, company announced Part 2 of the study is anticipated to conclude in the second half of 2025.
  • 10 Apr 2025 According to Galmed Pharmaceuticals media release, company announced positive preliminary results from Part 1 of the Ph1 Bioavailability AM-001 Study of Aramchol Meglumine
  • 13 Mar 2025 Planned End Date changed from 1 Apr 2025 to 1 May 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top